Brixtonbio
4 known investors
Brixton Bio develops Reneurx therapy, a treatment aimed at providing long-lasting pain relief for up to six months from a single administration. The company operates in the biotech and therapeutics space focused on pain control.
BiotechMedical Devices
Investors · 4
Non-dilutive funding · 1 SBIR/STTR award
Federal grants — no equity taken| Agency | Phase | Year | Amount |
|---|---|---|---|
| National Institutes of Health (NIH)National Institutes of Health | Phase ISTTR | 2022 | $252.1K |
Source: SBIR.gov award data (U.S. Small Business Administration). SBIR/STTR awards are competitive federal R&D grants and contracts — non-dilutive capital alongside any venture rounds above.
Frequently asked questions
- What does Brixtonbio do?
- Brixton Bio develops Reneurx therapy, a treatment aimed at providing long-lasting pain relief for up to six months from a single administration. The company operates in the biotech and therapeutics space focused on pain control.
- Who are Brixtonbio's investors?
- Brixtonbio's investors include Angel Physicians Fund, Excelestar Ventures, FemHealth Ventures, Schooner Capital.